Dr. KinyasHair Clinic · IstanbulLibrary ←
Science and Research Centre / Hair Loss and Treatments

Dr. Kinyas Hair Clinic · Science and Research Centre

Comparing Hair-Loss Treatments: Which Question Matters for You?

One ranking cannot choose the best treatment. Clarify cause, hair to preserve and acceptable treatment burden, then compare evidence, risks and uncertainty in one framework.

First: are diagnosis and goal the same?

AGA, telogen effluvium and scarring alopecias have different biology. Benefit in one does not prove equal effects in another. Relieving scalp symptoms, thickening hair and redistributing it surgically are also different goals. [1]

Explain what you want to change: shedding, visible loss, hairline or daily burden. Options gain meaning through goals and examination. The map below is not a prescription or GRADE assessment.

Which outcome are we comparing?

Counts, diameter, photographs and satisfaction are distinct. A treatment may improve one without outperforming on another. Different ages, sexes, baseline loss, durations and co-treatments prevent simple percentage rankings. [1], [2]

No difference found does not prove equivalence. Small pilots may lack power. Read design and missing follow-up alongside result tables.

Add current safety information

Older efficacy findings do not invalidate later safety updates. The 2025 EMA and 2026 MHRA reviews require molecule- and formulation-specific interpretation for finasteride/dutasteride. [3], [4]

Oral and topical minoxidil also differ in systemic risk. Convenience alone cannot decide. Other medicines, illnesses, pregnancy/fertility and tolerance matter. No self-adjustment or dose schedule follows from this page.

Link adjunct evidence to the actual product

PRP, needling and light have research, not proof of identical results across protocols, kits and devices. Combination trials answer a different question from standalone treatment. Detailed pages show these distinctions and access limits. [1], [2] (method comparison)

Mesotherapy defines no single ingredient. Cellular and vesicle preparations are not interchangeable. Trial registration is not marketing approval or proof for every use. Verify correspondence with the offered product. [5]

Expectations for supplements and shampoos

Deficiency treatment and mixed supplements are different questions. Positive product findings do not validate every mixture. Product- and study-specific assessment should replace a blanket weak-evidence-without-deficiency label; see the detailed supplement article.

Medicated-shampoo control of scalp disease is not AGA growth or graft survival. Cleansing, tolerance and follicular treatment should be separated. The cosmetics review supports this distinction. [6]

Considering surgery and medical therapy together

Transplantation redistributes donor hair rather than treating all ongoing causes. Medication can help some existing hair, but no drug or adjunct is mandatory for everyone. Discuss options you decline openly. [1]

With Dr. Kinyas, aim for a practical long-term plan rather than a top-ranked product. Establish baseline, review time, adverse-effect contact and alternatives. This text does not verify procedural roles, standard packages or clinic products.

What the studies do and do not establish
OptionFirst questionKey distinction
Topical minoxidilAGA diagnosis and scalp toleranceFormulation, sex and postoperative healing differ.
Oral minoxidilSystemic suitability and preferenceNot automatically better or risk-free.
FinasterideExisting hair in suitable menCurrent psychiatric/sexual safety information needed.
DutasteridePrevious response and individual riskLong elimination; doses/routes are not equivalent.
PRPGoal and preparation/protocolSatisfaction and graft survival differ.
MesotherapyExact injected contentsOral evidence cannot transfer to injection.
Laser/LEDDiagnosis and exact deviceOne device does not validate all devices.
MicroneedlingConcurrent treatmentNo automatic standalone effect or fresh-graft safety.
SpironolactoneFemale-pattern loss and suitabilityPregnancy, kidney/potassium and other medicines.
KetoconazoleScalp disease or growth?Dandruff control is not AGA treatment.
Vitamins/supplementsDeficiency and actual product researchMixture data do not validate one component or every brand.
Exosomes/cellular productsExact product and human researchMechanism, protocol, results and approval differ.

References and access limitations

This article is based on a targeted review of sources; it is not an original systematic review.

  1. Kanti V et al. Evidence-based (S3) guideline for AGA – short version. JEADV. 2018. DOI: 10.1111/jdv.14624.

    Guideline; 2015 search cut-off. New studies on topic pages; not treated as all current evidence.

  2. Penha MA et al. Oral Minoxidil vs Topical Minoxidil for Male AGA: A Randomized Clinical Trial. JAMA Dermatol. 2024. DOI: 10.1001/jamadermatol.2024.0284.

    Randomised study; prior relevant methods/results review. Primary/secondary endpoints separated. Not a direct comparison of all methods.

  3. EMA. Finasteride- and dutasteride-containing medicinal products; 2025 review.

    Safety review. Molecule/formulation differences and unknown frequency retained. Official referral page accessed on 2 November 2026.

  4. MHRA. Finasteride and Dutasteride — updated safety warnings. 11 May 2026.

    Regulatory update; official text accessed. Does not replace individual assessment or Turkish authorisation.

  5. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. 3 June 2021.

    Official regulatory information accessed; registration/approval distinction. Local status needs separate verification.

  6. Gavazzoni Dias MFR. Hair cosmetics: an overview. Int J Trichology. 2015;7:2–15. DOI: 10.4103/0974-7753.153450.

    Cosmetics review, not AGA or graft-survival trial.

← Back to section
WhatsApp
DR. KINYAS HAIR CLINIC

Quick Contact

Leave your details and we will contact you through your preferred channel.

How should we contact you?

Dr. Kinyas Hair Clinic uses your details to respond to your request and contact you.